Ovid Therapeutics Inc.
OVID | NASDAQ
$2.79
+$0.08 (+2.95%)
Sep 22, 2026, 1:15 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 7.25M | 566K | 392K | 1.5M | 208.38M | 12.62M |
Cost of Revenue | 300K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 6.95M | 566K | 392K | 1.5M | 208.38M | 12.62M |
Operating Income | -42.44M | -61.89M | -59.28M | -55.55M | 124.21M | -81.43M |
Interest Income | n/a | 3.9M | 4.9M | n/a | n/a | 395.4K |
Pretax Income | -17.41M | -26.43M | -52.34M | -54.17M | 124.16M | -81.04M |
Net Income | -17.41M | -26.43M | -52.34M | -54.17M | 122.83M | -81.04M |
Selling & General & Admin | 24.11M | 25.68M | 29.59M | 32.43M | 37.23M | 30.63M |
Research & Development | 25.58M | 36.77M | 28.59M | 24.62M | 46.94M | 64.12M |
Other Expenses | -300K | 1K | 1.5M | 510 | 1.1K | -700K |
Operating Expenses | 49.39M | 62.45M | 59.67M | 57.05M | 84.17M | 94.05M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 49.69M | 62.45M | 59.67M | 57.05M | 84.17M | 94.05M |
Income Tax Expense | n/a | n/a | n/a | n/a | 1.33M | n/a |
Shares Outstanding (Basic) | 73.74M | 70.91M | 70.58M | 70.43M | 67.48M | 58.45M |
Shares Outstanding (Diluted) | 73.74M | 70.91M | 70.58M | 70.43M | 68.07M | 58.45M |
EPS (Basic) | -0.24 | -0.37 | -0.74 | -0.77 | 1.78 | -1.39 |
EPS (Diluted) | -0.24 | -0.37 | -0.74 | -0.77 | 1.76 | -1.39 |
EBITDA | -17.11M | -57.77M | -57.01M | -54.17M | 124.45M | -81.12M |
EBIT | -17.41M | -58.39M | -57.58M | -55.55M | 124.21M | -81.43M |
Depreciation & Amortization | 300K | 613K | 568K | 1.38M | 237.08K | 306.85K |
Add to Watchlist
Select watchlists to add or remove OVID